Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. CEO Gregory D. Gorgas will represent the company, with an on-demand presentation available to registered attendees starting September 9 at 7:00 AM Eastern Time.
The presentation will be accessible via webcast on the conference platform and Artelo's investor relations website. Management will also engage in one-on-one meetings with qualified investors throughout the conference. Artelo focuses on modulating lipid-signaling pathways to develop treatments for cancer, pain, and dermatologic and neurological conditions.
Artelo Biosciences (Nasdaq: ARTL), un'azienda farmaceutica in fase clinica, ha annunciato la sua partecipazione alla 26a Conferenza Globale Annuale sugli Investimenti H.C. Wainwright che si terrà dal 9 all'11 settembre 2024 a New York City. Il CEO Gregory D. Gorgas rappresenterà l'azienda, con una presentazione on-demand disponibile per i partecipanti registrati a partire dal 9 settembre alle 7:00 AM ora orientale.
La presentazione sarà accessibile tramite webcast sulla piattaforma della conferenza e sul sito web delle relazioni con gli investitori di Artelo. La direzione parteciperà inoltre a incontri individuali con investitori qualificati durante tutta la conferenza. Artelo si concentra sulla modulazione delle vie di segnalazione lipidica per sviluppare trattamenti per il cancro, il dolore e condizioni dermatologiche e neurologiche.
Artelo Biosciences (Nasdaq: ARTL), una compañía farmacéutica en fase clínica, anunció su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright que se llevará a cabo del 9 al 11 de septiembre de 2024 en la ciudad de Nueva York. El CEO Gregory D. Gorgas representará a la compañía, con una presentación a demanda disponible para los asistentes registrados a partir del 9 de septiembre a las 7:00 AM, hora del este.
La presentación estará accesible a través de un webcast en la plataforma de la conferencia y en el sitio web de relaciones con inversores de Artelo. La dirección también se involucrará en reuniones uno a uno con inversores calificados durante toda la conferencia. Artelo se enfoca en modular las vías de señalización lipídica para desarrollar tratamientos para el cáncer, el dolor y condiciones dermatológicas y neurológicas.
아르텔로 생명과학(Artelo Biosciences) (Nasdaq: ARTL)는 임상 단계의 제약 회사로서, H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕시에서 열릴 예정입니다. CEO인 Gregory D. Gorgas가 회사를 대표하며, 9월 9일 오전 7시(동부 표준시)부터 등록된 참석자들에게 주문형 프레젠테이션이 제공됩니다.
프레젠테이션은 컨퍼런스 플랫폼과 아르텔로의 투자자 관계 웹사이트를 통해 웹캐스트로 접근할 수 있습니다. 경영진은 또한 컨퍼런스 기간 동안 자격을 갖춘 투자자들과 일대일 미팅을 진행할 예정입니다. 아르텔로는 암, 통증, 피부 및 신경학적 질환에 대한 치료제 개발을 위해 지질 신호 경로를 조절하는 데 집중하고 있습니다.
Artelo Biosciences (Nasdaq: ARTL), une entreprise pharmaceutique en phase clinique, a annoncé sa participation à la 26e Conférence Annuelle Globale sur l'Investissement H.C. Wainwright qui se tiendra du 9 au 11 septembre 2024 à New York. Le PDG Gregory D. Gorgas représentera l'entreprise, avec une présentation à la demande disponible pour les participants inscrits à partir du 9 septembre à 7h00, heure de l'Est.
La présentation sera accessible par webcast sur la plateforme de la conférence et sur le site des relations avec les investisseurs d'Artelo. La direction tiendra également des réunions individuelles avec des investisseurs qualifiés tout au long de la conférence. Artelo se concentre sur la modulation des voies de signalisation lipidique pour développer des traitements pour le cancer, la douleur et des conditions dermatologiques et neurologiques.
Artelo Biosciences (Nasdaq: ARTL), ein pharmazeutisches Unternehmen in der klinischen Phase, gab seine Teilnahme an der 26. jährlichen globalen Investmentkonferenz von H.C. Wainwright vom 9. bis 11. September 2024 in New York City bekannt. CEO Gregory D. Gorgas wird das Unternehmen vertreten, mit einer On-Demand-Präsentation, die für registrierte Teilnehmer ab dem 9. September um 7:00 Uhr Eastern Time verfügbar ist.
Die Präsentation wird über einen Webcast auf der Konferenzplattform und der Investor-Relations-Website von Artelo zugänglich sein. Das Management wird zudem während der gesamten Konferenz Eins-zu-eins-Meetings mit qualifizierten Investoren führen. Artelo konzentriert sich darauf, lipid-signalgebende Wege zu modulieren, um Behandlungen für Krebs, Schmerzen sowie dermatologische und neurologische Erkrankungen zu entwickeln.
- None.
- None.
SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions today announced that Gregory D. Gorgas, CEO of Artelo Biosciences, will be participating in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.
Artelo’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 9, 2024 at 7:00 AM Eastern Time. A webcast of the Company’s presentation can also be accessed at https://journey.ct.events/view/e83ca657-746a-443a-9769-d1e1a38009c4 and on the investor relations section of Artelo’s website at https://ir.artelobio.com/.
Management will be participating in one-on-one meetings with qualified members of the investor community throughout the conference in New York City. To request a meeting, please contact ARTL@crescendo-ir.com.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
When is Artelo Biosciences (ARTL) presenting at the H.C. Wainwright Global Investment Conference?
Where can investors access Artelo Biosciences' (ARTL) presentation for the H.C. Wainwright conference?
What is the focus of Artelo Biosciences' (ARTL) research and development?
How can investors request a meeting with Artelo Biosciences (ARTL) management at the H.C. Wainwright conference?
